This statement outlines a shared vision for the future of pulmonary arterial hypertension (PAH) care in the UK, with a focus on reducing time to accurate diagnosis – an issue which is …

2023年12月4日 · Essentially, the drug works by changing the expression of proteins that we know underly the familial [genetic] forms of the disease. So, rather than just opening up vessels, it …

2023年9月11日 · RAHWAY, N.J., Aug 25, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) (NYSE: MRK), today announced new analyses from studies of sotatercept, MSD’s …

MSD in the UK have published a policy consensus statement, A Shared Vision for Pulmonary Arterial Hypertension in the UK, with recommendations driven by expert insights outlining a …

2023年9月11日 · RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of …

2024年3月27日 · Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the …

For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We follow the science where we can make the greatest …

Home; About Us. Our History; Our Aims; Members; Associated Members; Board of Directors; Auditors; Scientific Committee; Staff and Consultants; Constitutional ...

2024年7月2日 · 머크 (MSD)가 새로운 계열에서 첫 약물인 폐동맥 고혈압 (PHA) 치료제 윈레바이어 (Winrevair, sotatercept)를 유럽에서 승인 지지를 받아, 강력한 경쟁을 예고하고 있다. 지난 주, …

2022年11月22日 · 머크(MSD)가 폐동맥 고혈압(PAH) 파이프라인 약품 소타테셉트(sotatercept)에 대한 긍정적인 3상 연구데티터를 보고한 후, 향후 PHA 시장에서 선도 약품이 될 것으로 예상된다.